MedTrace Logo

Urogenital Schistosomiasis and Sexually Transmitted Infections in Madagascar

NCT00713999 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 680

Last updated 2008-07-14

No results posted yet for this study

Summary

A cross-sectional study of urogenital schistosomiasis and sexually transmitted infections (STI) prevalence and associated morbidity in a rural community in Madagascar. Clearance of infections and resolution of morbidity were subsequently studied in two phases following systematic anti-STI and anti-schistosoma treatment, respectively.

Conditions

  • Sexually Transmitted Infections
  • Schistosoma Haematobium

Interventions

DRUG

Treatment with anti-STI and anti-schistosoma regimens

Anti-STI regimen: ciprofloxacin 500mg orally, doxycycline 100mg BID orally 7 days and metronidazole 2g orally (cefuroxime im and/or azithromycin alternatively for pregnant and breastfeeding women) Anti-schistosoma regimen: Praziquantel 40mg/kg

Sponsors & Collaborators

  • Statens Serum Institut

    collaborator OTHER

  • University of Aarhus

    lead OTHER

Principal Investigators

  • Peter DC Leutscher, MD, PhD · Danish Bilharziasis Laboratory

Study Design

Allocation
NA
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
15 Years
Max Age
49 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2001-08-31
Primary Completion
2002-04-30
Completion
2003-09-30

Countries

  • Madagascar

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00713999 on ClinicalTrials.gov